Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H4 | Q96RI1 | 16/20 | 0.55 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | USP2 | O75604 | 1/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.37 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.37 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18191611 | 0.96 | NR1H4 (0.56) | NR1H4HTTUSP2CYP3A4CYP2D6 | |
| SCHEMBL18191649 | 0.92 | NR1H4 (0.57) | NR1H4HTTCYP3A4CYP2D6CYP2C19 | |
| SCHEMBL18191622 | 0.92 | NR1H4 (0.60) | NR1H4HTT | |
| SCHEMBL18191630 | 0.90 | NR1H4 (0.57) | NR1H4USP2CYP3A4CYP2D6CYP2C19 | |
| SCHEMBL18191643 | 0.90 | NR1H4 (0.57) | NR1H4USP2CYP3A4CYP2D6CYP2C19 | |
| SCHEMBL21574208 | 0.89 | NR1H4 (0.53) | NR1H4 | |
| SCHEMBL18191596 | 0.87 | NR1H4 (0.55) | NR1H4 | |
| SCHEMBL18191661 | 0.86 | NR1H4 (0.63) | NR1H4 | |
| SCHEMBL18191667 | 0.86 | NR1H4 (0.59) | NR1H4HTT | |
| SCHEMBL18191585 | 0.86 | NR1H4 (0.59) | NR1H4HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3288948-B1 | FUSED TRICYCLIC PYRAZOLE DERIVATIVES USEFUL FOR MODULATING FARNESOID X RECEPTORS | NOVARTIS AG (CH) | 2019-11-20 | — | — | EP | claimed |
| US-10351576-B2 | Fused tricyclic pyrazole derivatives useful for farnesoid X receptors | NOVARTIS AG (CH) | 2019-07-16 | — | — | US | claimed |
| US-20180298018-A1 | FUSED TRICYCLIC PYRAZOLE DERIVATIVES USEFUL FOR FARNESOID X RECEPTORS | NOVARTIS AG (CH) | 2018-10-18 | — | — | US | claimed |
| EP-3288948-A1 | FUSED TRICYCLIC PYRAZOLE DERIVATIVES USEFUL FOR MODULATING FARNESOID X RECEPTORS | Novartis AG (CH) | 2018-03-07 | — | — | EP | claimed |
| WO-2016174616-A1 | FUSED TRICYCLIC PYRAZOLE DERIVATIVES USEFUL FOR MODULATING FARNESOID X RECEPTORS | NOVARTIS AG (CH) | 2016-11-03 | — | — | WO | claimed |
| EP-3288948-B1 | FUSED TRICYCLIC PYRAZOLE DERIVATIVES USEFUL FOR MODULATING FARNESOID X RECEPTORS | NOVARTIS AG (CH) | 2019-11-20 | — | — | EP | disclosed |
| US-10351576-B2 | Fused tricyclic pyrazole derivatives useful for farnesoid X receptors | NOVARTIS AG (CH) | 2019-07-16 | — | — | US | disclosed |
| US-10351576-B2 | Fused tricyclic pyrazole derivatives useful for farnesoid X receptors | NOVARTIS AG (CH) | 2019-07-16 | — | — | US | disclosed |
| US-20180298018-A1 | FUSED TRICYCLIC PYRAZOLE DERIVATIVES USEFUL FOR FARNESOID X RECEPTORS | NOVARTIS AG (CH) | 2018-10-18 | — | — | US | disclosed |
| EP-3288948-A1 | FUSED TRICYCLIC PYRAZOLE DERIVATIVES USEFUL FOR MODULATING FARNESOID X RECEPTORS | Novartis AG (CH) | 2018-03-07 | — | — | EP | disclosed |
| WO-2016174616-A1 | FUSED TRICYCLIC PYRAZOLE DERIVATIVES USEFUL FOR MODULATING FARNESOID X RECEPTORS | NOVARTIS AG (CH) | 2016-11-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180298018-A1 | FUSED TRICYCLIC PYRAZOLE DERIVATIVES USEFUL FOR FARNESOID X RECEPTORS | NR1H4, FXR1, GPBAR1 | NR1H4 1/4885HTT 4838/4885USP2 4300/4885 |
| US-10351576-B2 | Fused tricyclic pyrazole derivatives useful for farnesoid X receptors | NR1H4, FXR1, GPBAR1 | NR1H4 1/4885HTT 4838/4885USP2 4300/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.